PAVmed (PAVM) 10-Q 12 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Jun. 30, 2024	Aug. 08, 2024
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-37685
Entity Registrant Name	PAVMED INC.
Entity Central Index Key	0001624326
Entity Tax Identification Number	47-1214177
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	360 Madison Avenue
Entity Address, Address Line Two	25th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	(917)
Local Phone Number	813-1828
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	10,010,844	10,406,433
Entity Listing, Par Value Per Share	$ 0.001
Common Stock [Member]
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	PAVM
Security Exchange Name	NASDAQ
Series Z Warrants, each to Purchase 1/15th of One Share of Common Stock [Member]
Title of 12(b) Security	Series Z Warrants, each to purchase 1/15th of one share of Common Stock
Trading Symbol	PAVMZ
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash	$ 25,499	$ 19,639
Accounts receivable	219	61
Inventory	687	278
Prepaid expenses, deposits, and other current assets	3,802	4,520
Total current assets	30,207	24,498
Fixed assets, net	1,331	1,783
Operating lease right-of-use assets	5,771	4,267
Intangible assets, net	947	1,424
Other assets	1,157	1,147
Total assets	39,413	33,119
Current liabilities:
Accounts payable	1,232	1,786
Accrued expenses and other current liabilities	6,789	6,626
Operating lease liabilities, current portion	1,369	1,565
Senior Secured Convertible Notes - at fair value	44,000	44,200
Total current liabilities	53,390	54,177
Operating lease liabilities, less current portion	4,665	2,960
Total liabilities	58,055	57,137
Commitments and contingencies (Note 8)
Stockholders’ Equity:
Preferred stock, $0.001 par value. Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, par value $0.001, issued and outstanding 1,357,976 at June 30, 2024 and 1,305,213 shares at December 31, 2023	3,151	2,993
Common stock, $0.001 par value. Authorized, 50,000,000 shares; 9,554,381 and 8,578,505 shares outstanding as of June 30, 2024 and December 31, 2023, respectively	10	9
Additional paid-in capital	243,524	237,600
Accumulated deficit	(320,630)	(294,433)
Total PAVmed Inc. Stockholders’ Equity (Deficit)	(73,945)	(53,831)
Noncontrolling interests	55,303	29,813
Total Stockholders’ Equity (Deficit)	(18,642)	(24,018)
Total Liabilities and Stockholders’ Equity (Deficit)	$ 39,413	$ 33,119

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares outstanding	9,554,381	8,578,505
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued	1,357,976	1,305,213
Preferred stock, shares outstanding	1,357,976	1,305,213

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenue		$ 979	$ 166	$ 1,989	$ 612
Operating expenses:
Cost of revenue		1,666	1,685	3,411	3,030
Sales and marketing		4,242	4,339	8,552	8,877
General and administrative		7,009	6,652	13,688	17,060
Amortization of acquired intangible assets		105	505	477	1,010
Research and development		1,641	3,469	3,583	7,519
Total operating expenses		14,663	16,650	29,711	37,496
Operating loss		(13,684)	(16,484)	(27,722)	(36,884)
Other income (expense):
Interest income		110	163	182	283
Interest expense		(11)	(228)	(26)	(411)
Change in fair value - Senior Secured Convertible Notes		(566)	(340)	(2,728)	(1,380)
Loss on issue and offering costs - Senior Secured Convertible Note					(1,186)
Debt extinguishments loss - Senior Secured Convertible Notes		(763)	(743)	(1,132)	(1,268)
Debt modification expense				(2,000)
Change in fair value - derivative liability			(260)		(260)
Gain on sale of intellectual property					1,000
Other income (expense), net		(1,230)	(1,408)	(5,704)	(3,222)
Loss before provision for income tax		(14,914)	(17,892)	(33,426)	(40,106)
Provision for income taxes
Net loss before noncontrolling interests		(14,914)	(17,892)	(33,426)	(40,106)
Net loss attributable to the noncontrolling interests		4,087	3,355	7,387	7,638
Net loss attributable to PAVmed Inc.		(10,827)	(14,537)	(26,039)	(32,468)
Less: Series B Convertible Preferred Stock dividends earned		(81)	(75)	(161)	(149)
Less: Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests				(7,496)
Net loss attributable to PAVmed Inc. common stockholders		$ (10,908)	$ (14,612)	$ (33,696)	$ (32,617)
Per share information:
Net loss per share attributable to PAVmed Inc. common stockholders - diluted	[1]	$ (1.19)	$ (2.10)	$ (3.78)	$ (4.86)
Net loss per share attributable to PAVmed Inc. common stockholders - basic	[1]		$ (2.10)		$ (4.86)
Weighted average common shares outstanding, basic		9,152,819	6,956,655	8,923,862	6,716,169
Weighted average common shares outstanding, diluted		9,152,819	6,956,655	8,923,862	6,716,169
[1]- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	$ 2,695	$ 6	$ 216,195	$ (228,169)	$ (408)	$ 20,615	$ 10,934
Balance, shares at Dec. 31, 2022	1,205,759	6,300,703
Balance at Mar. 31, 2023	$ 2,767	$ 7	221,341	(246,172)		32,861	10,804
Balance, shares at Mar. 31, 2023	1,229,887	6,706,427
Balance at Dec. 31, 2022	$ 2,695	$ 6	216,195	(228,169)	(408)	20,615	10,934
Balance, shares at Dec. 31, 2022	1,205,759	6,300,703
Dividends declared - Series B Convertible Preferred Stock	$ 146			(146)
Dividends declared - Series B Convertible Preferred Stock, shares	48,738
Issue common stock - PAVM ATM Facility			1,166				1,166
Issue common stock - PAVM ATM Facility, shares		155,384
Vest - restricted stock awards
Vest - restricted stock awards, shares		6,666
Conversions - Senior Secured Convertible Note		$ 1	4,422				4,423
Conversions - Senior Secured Convertible Note, shares		634,899
Impact of subsidiary equity transactions			1,332			(1,332)
Issuance - vendor service agreement			600			147	747
Issuance - vendor service agreement, shares		100,000
Stock-based compensation - PAVmed Inc.			2,288				2,288
Stock-based compensation - subsidiaries			646			3,992	4,638
Net Loss				(32,468)		(7,638)	(40,106)
Purchase - Employee Stock Purchase Plan			122		60		182
Purchase - Employee Stock Purchase Plan, shares		25,626
Purchase - subsidiary common stock - Employee Stock Purchase Plan						276	276
Issuance - subsidiary common stock - Committed Equity Facility, net of financing charges						284	284
Issuance - subsidiary common stock - Settlement APA-RDx - Installment Payment						713	713
Issuance - subsidiary preferred stock (Series A)						13,625	13,625
Treasury stock			(348)		348
Treasury stock, shares		12,589
Balance at Jun. 30, 2023	$ 2,841	$ 7	226,423	(260,783)		30,682	(830)
Balance, shares at Jun. 30, 2023	1,254,497	7,235,867
Balance at Dec. 31, 2022	$ 2,695	$ 6	216,195	(228,169)	(408)	20,615	10,934
Balance, shares at Dec. 31, 2022	1,205,759	6,300,703
Balance at Dec. 31, 2023	$ 2,993	$ 9	237,600	(294,433)		29,813	(24,018)
Balance, shares at Dec. 31, 2023	1,305,213	8,578,505
Balance at Mar. 31, 2023	$ 2,767	$ 7	221,341	(246,172)		32,861	10,804
Balance, shares at Mar. 31, 2023	1,229,887	6,706,427
Dividends declared - Series B Convertible Preferred Stock	$ 74			(74)
Dividends declared - Series B Convertible Preferred Stock, shares	24,610
Issue common stock - PAVM ATM Facility			609				609
Issue common stock - PAVM ATM Facility, shares		83,250
Conversions - Senior Secured Convertible Note			2,395				2,395
Conversions - Senior Secured Convertible Note, shares		346,190
Impact of subsidiary equity transactions			143			(143)
Issuance - vendor service agreement			600			147	747
Issuance - vendor service agreement, shares		100,000
Stock-based compensation - PAVmed Inc.			1,090				1,090
Stock-based compensation - subsidiaries			245			1,172	1,417
Net Loss				(14,537)		(3,355)	(17,892)
Balance at Jun. 30, 2023	$ 2,841	$ 7	226,423	(260,783)		30,682	(830)
Balance, shares at Jun. 30, 2023	1,254,497	7,235,867
Balance at Dec. 31, 2023	$ 2,993	$ 9	237,600	(294,433)		29,813	(24,018)
Balance, shares at Dec. 31, 2023	1,305,213	8,578,505
Balance at Mar. 31, 2024	$ 3,071	$ 9	237,863	(309,723)		48,205	(20,575)
Balance, shares at Mar. 31, 2024	1,331,336	8,858,597
Balance at Dec. 31, 2023	$ 2,993	$ 9	237,600	(294,433)		29,813	(24,018)
Balance, shares at Dec. 31, 2023	1,305,213	8,578,505
Dividends declared - Series B Convertible Preferred Stock	$ 158			(158)
Dividends declared - Series B Convertible Preferred Stock, shares	52,763
Issue common stock - PAVM ATM Facility			693				693
Issue common stock - PAVM ATM Facility, shares		333,299
Vest - restricted stock awards
Vest - restricted stock awards, shares		4,064
Conversions - Senior Secured Convertible Note		$ 1	1,112				1,113
Conversions - Senior Secured Convertible Note, shares		574,424
Conversions - subsidiary common stock - Senior Secured Convertible Note						2,541	2,541
Impact of subsidiary equity transactions			2,169			(2,169)
Issuance - vendor service agreement			50			401	451
Issuance - vendor service agreement, shares		29,757
Stock-based compensation - PAVmed Inc.			1,532				1,532
Stock-based compensation - subsidiaries			306			1,948	2,254
Net Loss				(26,039)		(7,387)	(33,426)
Exercise - stock options of subsidiary						4	4
Purchase - Employee Stock Purchase Plan			62				62
Purchase - Employee Stock Purchase Plan, shares		34,332
Purchase - subsidiary common stock - Employee Stock Purchase Plan						353	353
Issuance - subsidiary preferred stock (Series A-1)						5,670	5,670
Exchange - subsidiary preferred stock (Series A and Series A-1)						(24,294)	(24,294)
Issuance - subsidiary preferred stock (Series B and Series B-1)						55,919	55,919
Subsidiary deemed dividends on preferred stock attributable to noncontrolling interests						(7,496)	(7,496)
Balance at Jun. 30, 2024	$ 3,151	$ 10	243,524	(320,630)		55,303	(18,642)
Balance, shares at Jun. 30, 2024	1,357,976	9,554,381
Balance at Mar. 31, 2024	$ 3,071	$ 9	237,863	(309,723)		48,205	(20,575)
Balance, shares at Mar. 31, 2024	1,331,336	8,858,597
Dividends declared - Series B Convertible Preferred Stock	$ 80			(80)
Dividends declared - Series B Convertible Preferred Stock, shares	26,640
Issue common stock - PAVM ATM Facility			198				198
Issue common stock - PAVM ATM Facility, shares		200,000
Vest - restricted stock awards
Vest - restricted stock awards, shares		4,064
Conversions - Senior Secured Convertible Note		$ 1	805				806
Conversions - Senior Secured Convertible Note, shares		461,963
Conversions - subsidiary common stock - Senior Secured Convertible Note						1,854	1,854
Impact of subsidiary equity transactions			3,903			(3,903)
Issuance - vendor service agreement			50			401	451
Issuance - vendor service agreement, shares		29,757
Issuance - subsidiary preferred stock (Series B-1)						11,634	11,634
Stock-based compensation - PAVmed Inc.			598				598
Stock-based compensation - subsidiaries			107			1,199	1,306
Net Loss				(10,827)		(4,087)	(14,914)
Balance at Jun. 30, 2024	$ 3,151	$ 10	$ 243,524	$ (320,630)		$ 55,303	$ (18,642)
Balance, shares at Jun. 30, 2024	1,357,976	9,554,381

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss - before noncontrolling interest (“NCI”)	$ (14,914)	$ (17,892)	$ (33,426)	$ (40,106)
Adjustments to reconcile net loss - before NCI to net cash used in operating activities
Depreciation and amortization expense			891	1,474
Stock-based compensation	1,904	2,507	3,786	6,926
Gain on sale of intellectual property				(1,000)
APA-RDx: Issue common stock of subsidiary - termination payment				713
Amortization of common stock payment for vendor service agreement			163	625
Change in fair value - Senior Secured Convertible Notes	566	340	2,728	1,380
Loss on issue - Senior Secured Convertible Note				1,111
Debt extinguishment loss - Senior Secured Convertible Note	763	743	1,132	1,268
Change in fair value - derivative liability		260		260
Non-cash lease expense			5	192
Changes in operating assets and liabilities:
Accounts receivable			(158)	(24)
Prepaid expenses, deposits and current and other assets			380	(1,592)
Accounts payable			(553)	(1,541)
Accrued expenses and other current liabilities			287	1,241
Net cash flows used in operating activities			(24,765)	(29,073)
Cash flows from investing activities
Purchase of equipment			(45)	(41)
Proceeds from sale of intellectual property				1,000
Net cash flows provided by (used in) investing activities			(45)	959
Cash flows from financing activities
Proceeds – issue of preferred stock - subsidiary			29,798	13,625
Proceeds – issue of Senior Secured Convertible Note				10,000
Payment – Senior Secured Convertible Note – acceleration floor payments			(531)
Proceeds – issue of common stock - At-The-Market Facility			984	1,166
Proceeds – subsidiary common stock - Committed Equity Facility and At-The-Market Facility				284
Proceeds – issue common stock – Employee Stock Purchase Plan			62	182
Proceeds – subsidiary common stock – Employee Stock Purchase Plan			353	276
Proceeds – exercise of stock options issued under equity plan of subsidiary			4
Net cash flows provided by financing activities			30,670	25,533
Net increase (decrease) in cash			5,860	(2,581)
Cash, beginning of period			19,639	39,744
Cash, end of period	$ 25,499	$ 37,163	$ 25,499	$ 37,163

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (10,827)	$ (14,537)	$ (26,039)	$ (32,468)

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

The Company

The Company	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	Note 1 — The Company Description of the Business PAVmed is structured to be a multi-product life sciences company organized to advance a pipeline of innovative healthcare technologies. Led by a team of highly skilled personnel with a track record of bringing innovative products to market, PAVmed is focused on innovating, developing, acquiring, and commercializing novel products that target unmet medical needs with large addressable market opportunities. Leveraging our corporate structure—a parent company that will establish distinct subsidiaries for each financed asset—we have the flexibility to raise capital at the PAVmed level to fund product development, or to structure financing directly into each subsidiary in a manner tailored to the applicable product, the latter of which is our current strategy given prevailing market conditions. Our current focus is multi-fold. We continue to pursue commercial expansion and execution of EsoGuard, which is the flagship product of our subsidiary Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”). In addition, through a separate majority-owned subsidiary, Veris Health (“Veris”), we are focused on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Platform. In terms of other existing products and technologies, we have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization. Finally, as resources permit, we will continue to explore external innovations that fulfill our project selection criteria without limiting ourselves to any target sector, specialty or condition.

Liquidity and Going Concern

Liquidity and Going Concern	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	Note 2 — Liquidity and Going Concern The Company’s management is required to assess the Company’s ability to continue as a going concern for the one year period following the date of the financial statements being issued. In each reporting period, including interim periods, an entity is required to assess conditions known and reasonably knowable as of the financial statement issuance date to determine whether it is probable an entity will not meet its financial obligations within one year from the financial statement issuance date. Substantial doubt about an entity’s ability to continue as a going concern exists when conditions and events, considered in the aggregate, indicate it is probable the entity will be unable to meet its financial obligations as they become due within one year after the date the financial statements are issued. The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company generated $ 1.0 2.0 The Company incurred a net loss attributable to PAVmed Inc. common stockholders of approximately $ 33.7 24.8 23.2 44.0 25.5 The Company’s ability to continue operations 12 months beyond the issuance of the financial statements, will depend upon generating substantial revenue that is conditioned upon obtaining positive third-party reimbursement coverage for its EsoGuard Esophageal DNA Test from both government and private health insurance providers, increasing revenue through contracting directly with self-insured employers, and on its ability to raise additional capital through various potential sources including equity and/or debt financings or refinancing existing debt obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are issued.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 — Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on March 25, 2024, except as otherwise noted herein below. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of PAVmed and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned subsidiaries, majority-owned subsidiaries and Lucid Diagnostics. All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in each of: Lucid Diagnostics and Veris Health, with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. See Note 14, Noncontrolling Interest As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The unaudited condensed consolidated results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 25, 2024. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts. Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Note 3 — Summary of Significant Accounting Policies Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients Note 3 — Summary of Significant Accounting Policies Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, which are accounted under the “fair value option election” as discussed below. Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, which is accounted under the “fair value option election” as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 9, Financial Instruments Fair Value Measurements Debt Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss. Recent Accounting Standards Updates Not Yet Adopted In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Note 4 — Revenue from Contracts with Customers Revenue Recognized In the three and six month periods ended June 30, 2024, the Company recognized total revenue of $ 979 1,989 166 612 Cost of Revenue The cost of revenues principally includes the costs related to the Company’s laboratory operations (excluding estimated costs associated with research activities), the costs related to the EsoCheck cell collection device, cell sample mailing kits and license royalties. In the three and six month periods ended June 30, 2024, the cost of revenue was $ 1,666 3,411 1,685 3,030

Prepaid Expenses, Deposits, and

Prepaid Expenses, Deposits, and Other Current Assets	6 Months Ended
	Jun. 30, 2024
Prepaid Expenses Deposits And Other Current Assets
Prepaid Expenses, Deposits, and Other Current Assets	Note 5 — Prepaid Expenses, Deposits, and Other Current Assets Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets June 30, 2024 December 31, 2023 Advanced payments to service providers and suppliers $ 738 $ 739 Prepaid insurance 872 848 Deposits 1,896 2,672 Veris Box supplies 296 261 Total prepaid expenses, deposits and other current assets $ 3,802 $ 4,520

Leases

Leases	6 Months Ended
	Jun. 30, 2024
Leases
Leases	Note 6 — Leases During the six months ended June 30, 2024, the Company entered into additional lease agreements that have commenced and are classified as operating leases, including in June 2024, Lucid exercised a renewal option to extend the lease term on its central laboratory in California for an additional three years through December 31, 2027. The aggregate (undiscounted) rent payments are approximately $ 2.6 The Company’s future lease payments as of June 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Minimum Lease Payments for Operating Leases 2024 (remainder of year) $ 909 2025 1,724 2026 1,677 2027 1,507 2028 472 Thereafter 848 Total lease payments $ 7,137 Less: imputed interest (1,103 ) Present value of lease liabilities $ 6,034 Note 6 — Leases Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases 2024 2023 Six Months Ended June 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 942 $ 705 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,285 $ 2,689 Weighted-average remaining lease term - operating leases (in years) 4.40 4.75 Weighted-average discount rate - operating leases 7.875 % 7.875 % As of June 30, 2024 and December 31, 2023, the Company’s right-of-use assets from operating leases were $ 5,771 4,267 6,034 4,525 1,369 1,565 4,665 2,960

Intangible Assets, net

Intangible Assets, net	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, net	Note 7 — Intangible Assets, net Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated Amortization Estimated Useful Life June 30, 2024 December 31, 2023 Defensive asset 60 $ 2,105 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 3,200 Other 1 year 70 70 Total Intangible assets 5,375 5,375 Less Accumulated Amortization (4,428 ) (3,951 ) Intangible Assets, net $ 947 $ 1,424 Amortization expense of the intangible assets discussed above was $ 105 505 477 1,010 Schedule of Estimated Amortization Expense for Intangible Assets 2024 (remainder of year) $ 210 2025 421 2026 316 Total $ 947

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	Note 8 — Commitment and Contingencies Other Matters In the ordinary course of PAVmed business, particularly as it begins commercialization of its products, the Company may be subject to certain other legal actions and claims, including product liability, consumer, commercial, tax and governmental matters, which may arise from time to time. The Company is not aware of any such pending legal or other proceedings that are reasonably likely to have a material impact on the Company. Notwithstanding, legal proceedings are subject-to inherent uncertainties, and an unfavorable outcome could include monetary damages, and excessive verdicts can result from litigation, and as such, could result in a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows. Additionally, although the Company has specific insurance for certain potential risks, the Company may in the future incur judgments or enter into settlements of claims which may have a material adverse impact on the Company’s business, financial position, results of operations, and /or cash flows.

Financial Instruments Fair Valu

Financial Instruments Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Financial Instruments Fair Value Measurements	Note 9 — Financial Instruments Fair Value Measurements Recurring Fair Value Measurements The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total June 30, 2024 Senior Secured Convertible Note - April 2022 $ — $ — $ 19,200 $ 19,200 Senior Secured Convertible Note - September 2022 — — 13,600 13,600 Lucid Senior Secured Convertible Note - March 2023 — — 11,200 11,200 Totals $ — $ — $ 44,000 $ 44,000 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total December 31, 2023 Senior Secured Convertible Note - April 2022 $ — $ — $ 19,000 $ 19,000 Senior Secured Convertible Note - September 2022 — — 11,250 11,250 Lucid Senior Secured Convertible Note - March 2023 — — 13,950 13,950 Totals $ — $ — $ 44,200 $ 44,200 1 There were no transfers between the respective Levels during the six months ended June 30, 2024. As discussed in Note 10, Debt 27.5 11.25 As discussed in Note 10, Debt, 11.1 The estimated fair value of the financial instruments classified within the Level 3 category was determined using both observable inputs and unobservable inputs. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs. Note 9 — Financial Instruments Fair Value Measurements The estimated fair value of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as of each of June 30, 2024 and December 31, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used April 2022 Senior September 2022 Senior Lucid March 2023 Senior Fair Value $ 19,200 $ 13,600 $ 11,200 Face value principal payable $ 17,602 $ 8,082 $ 9,811 Required rate of return 10.000 % 9.700 % 10.00 % Conversion Price $ 75.00 $ 75.00 $ 5.00 Value of common stock $ 0.82 $ 0.82 $ 0.82 Expected term (years) 0.76 1.19 0.72 Volatility 160.00 % 160.00 % 60.00 % Risk free rate 5.07 % 4.90 % 5.09 % Dividend yield — % — % — % April 2022 Senior September 2022 Senior Lucid March 2023 Senior Fair Value $ 19,000 $ 11,250 $ 13,950 Face value principal payable $ 17,602 $ 9,062 $ 11,019 Required rate of return 10.00 10.50 % 10.00 10.20 % 10.00 % Conversion Price $ 75.00 $ 75.00 $ 5.00 Value of common stock $ 4.12 $ 4.12 $ 1.41 Expected term (years) 0.26 1.26 0.69 1.69 1.22 Volatility 85.00 % 85.00 % 60.00 % Risk free rate 4.54 5.25 % 4.31 4.96 % 4.56 % Dividend yield — % — % — % The estimated fair values recognized utilized PAVmed’s and Lucid’s common stock prices, along with certain Level 3 inputs (as presented in the respective tables above), in the development of Monte Carlo simulation models, discounted cash flow analyses, and /or Black-Scholes valuation models. The estimated fair values are subjective and are affected by changes in inputs to the valuation models and analyses, including the respective common stock prices, as compared to the floor price on conversions, the dividend yields, the risk-free rates based on U.S. Treasury security yields, and certain other Level-3 inputs including, assumptions regarding the estimated volatility in the value of the respective common stock prices. Changes in these assumptions can materially affect the recognized estimated fair values.

Debt

Debt	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Debt	Note 10 — Debt The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,200 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 8,082 13,600 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 9,811 11,200 Balance as of June 30, 2024 $ 35,495 $ 44,000 Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,000 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 9,062 11,250 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 11,019 13,950 Balance as of December 31, 2023 $ 37,683 $ 44,200 The changes in the fair value of debt during the three and six month periods ended June 30, 2024 is as follows: Schedule of Changes in Fair Value of Debt April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - March 31, 2024 $ 18,800 $ 13,600 $ 13,140 $ 45,540 $ — Installment repayments – common stock — (700 ) (1,125 ) (1,825 ) — Non-installment payments – common stock — (65 ) (216 ) (281 ) — Change in fair value 400 765 (599 ) 566 (566 ) Fair Value at June 30, 2024 $ 19,200 $ 13,600 $ 11,200 $ 44,000 - Other Income (Expense) - Change in fair value – three month period ended June 30, 2024 $ (566 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2023 $ 19,000 $ 11,250 $ 13,950 $ 44,200 $ — Installment repayments – common stock — (980 ) (1,208 ) (2,188 ) — Non-installment payments – common stock — (88 ) (652 ) (740 ) — Change in fair value 200 3,418 (890 ) 2,728 (2,728 ) Fair Value at June 30, 2024 $ 19,200 $ 13,600 $ 11,200 $ 44,000 - Other Income (Expense) - Change in fair value – six month period ended June 30, 2024 $ (2,728 ) Note 10 — Debt The changes in the fair value of debt during the three and six month periods ended June 30, 2023 is as follows: April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - March 31, 2023 $ 20,750 $ 11,650 $ 11,900 $ 44,300 $ — Installment repayments – common stock (1,608 ) — — (1,608 ) — Non-installment payments – common stock (42 ) — — (42 ) — Change in fair value 430 200 (290 ) 340 (340 ) Fair Value at June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 - Other Income (Expense) - Change in fair value – three month period ended June 30, 2023 $ (340 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2022 $ 22,000 $ 11,650 $ — $ 33,650 $ — Fair Value - Beginning of Period $ 22,000 $ 11,650 $ — $ 33,650 $ — Face value principal – issue date — — 11,111 11,111 — Fair value adjustment – issue date — — 789 789 (789 ) Installment repayments – common stock (2,943 ) — — (2,943 ) — Non-installment payments – common stock (208 ) — — (208 ) — Change in fair value 681 200 (290 ) 591 (591 ) Fair Value at June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 - Fair Value - Ending of Period $ 19,530 $ 11,850 $ 11,610 $ 42,990 - Other Income (Expense) - Change in fair value – six month period ended June 30, 2023 $ (1,380 ) PAVmed - Senior Secured Convertible Notes The Company entered into a Securities Purchase Agreement (“SPA”) dated March 31, 2022, with an accredited institutional investor (“Investor”, “Lender”, and /or “Holder”), wherein, the Company agreed to sell, and the Investor agreed to purchase an aggregate of $ 50.0 27.5 22.5 Under the SPA, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, with such note having a $ 27.5 7.875 75.00 April 4, 2024 maturity date the investor agreed to extend by one year, to April 4, 2025 Under the same SPA, the Company issued an additional Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, with such note having a $ 11.25 7.875 75.00 September 6, 2024 maturity date the investor agreed to extend by one year, to September 8, 2025. Note 10 — Debt The Company has agreed to reduce temporarily, and the Investor has consented to reducing temporarily, the contractual conversion price under the April 2022 Senior Convertible Note and the September 2022 Senior Convertible Note to equal to 82.5 0.40 1 The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, to not exceed 30% (the “Debt to Market Cap Ratio Test”); and (iii) the Company’s market capitalization to at no time be less than $75 million In consideration of the covenant waiver and maturity extensions discussed above, the Company agreed to pay the holder of the notes $ 2,000 The April 2022 Senior Convertible Note and September 2022 Senior Convertible Note installment payments may be made in shares of PAVmed common stock at a conversion price that is the lower of the contractual conversion price and 82.5 2.70 In the three and six month periods ended June 30, 2024, approximately $ 700 and $ 980 , respectively, of principal repayments along with approximately $ 65 and $ 88 , respectively, of interest expense thereon, were settled through the issuance of 461,963 and 574,424 , respectively, shares of common stock of the Company, with such shares having a fair value of approximately $ 805 and $ 1,113 , respectively, (with such fair value measured as the respective conversion date quoted closing price of the common stock of the Company). In addition, during the three and six month periods ended June 30, 2024, the Company paid $ 209 and $ 407 , respectively, in cash related to acceleration floor payments on these notes related to the conversion price being below the floor price, which is included in debt extinguishment loss on the Company’s unaudited condensed consolidated statements of operations. The conversions and cash paid resulted in debt extinguishment losses of $ 249 and $ 452 in the three and six month periods ended June 30, 2024, respectively. Lucid Diagnostics - Senior Secured Convertible Note Lucid Diagnostics entered into a Securities Purchase Agreement (“Lucid SPA”) dated March 13, 2023, with an accredited institutional investor (“Investor”, “Lender”, and /or “Holder”), wherein, Lucid agreed to sell, and the Investor agreed to purchase an aggregate of $ 11.1 Under the SPA dated March 13, 2023, Lucid issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, with such note having a $ 11.1 7.875 5.00 March 21, 2025 The Lucid March 2023 Senior Convertible Note proceeds were $ 9.925 1.186 During the period from March 21, 2023 to September 20, 2023, Lucid was required to pay interest expense only (on the $ 11.1 7.875 219 243 Commencing September 21, 2023, and then on each of the successive first and tenth trading day of each month thereafter through to and including March 14, 2025 (each referred to as an “Installment Date”); and on the March 21, 2025 292 Note 10 — Debt In addition to the Installment Amount repayments, the Holder may elect to accelerate the conversion of future Installment Amount repayments, and interest thereon, subject to certain restrictions, as defined, utilizing the then current conversion price of the most recent Installment Date conversion price. The payment of all amounts due and payable under this senior convertible note is guaranteed by Lucid’s subsidiaries; and the obligations under this senior convertible note are secured by all of the assets of Lucid and its subsidiaries. Lucid is subject to certain customary affirmative and negative covenants regarding the rank of the note, along with the incurrence of further indebtedness, the existence of liens, the repayment of indebtedness and the making of investments, the payment of cash in respect of dividends, distributions or redemptions, the transfer of assets, the maturity of other indebtedness, and transactions with affiliates, among other customary matters. Lucid is subject to financial covenants requiring: (i) a minimum of $5.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) Lucid’s average market capitalization over the prior ten trading days, as of the last day of any fiscal quarter commencing with September 30, 2023, to not exceed 30%; and (iii) Lucid’s market capitalization to at no time be less than $30 million. The Lucid March 2023 Senior Convertible Note installment payments may be made in shares of Lucid Diagnostics common stock at a conversion price that is the lower of the contractual conversion price and 82.5 0.30 In the three and six month periods ended June 30, 2024, approximately $ 1,125 and $ 1,208 , respectively, of principal repayments along with approximately $ 215 and $ 652 , respectively, of interest expense thereon, were settled through the issuance of 2,117,833 and 2,661,181 , respectively, shares of common stock of Lucid, with such shares having a fair value of approximately $ 1,854 and $ 2,541 , respectively, (with such fair value measured as the respective conversion date quoted closing price of the common stock of Lucid). The conversions resulted in debt extinguishment losses of $ 512 and $ 681 in the three and six month periods ended June 30, 2024, respectively. Subsequent to June 30, 2024, as of August 8, 2024, approximately $ 375 of principal repayments along with approximately $ 80 of interest expense thereon, was settled through the issuance of 747,909 shares of common stock of Lucid, with such shares having a fair value of approximately $ 619 (with such fair value measured as the respective conversion date quoted closing price of the common stock of Lucid). During the three and six month periods ended June 30, 2024, the Company recognized debt extinguishment losses in total of approximately $ 763 1,132 743 1,268 See Note 9, Financial Instruments Fair Value Measurements

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2024
Retirement Benefits [Abstract]
Stock-Based Compensation	Note 11 — Stock-Based Compensation PAVmed Inc. 2014 Long-Term Incentive Equity Plan The PAVmed Inc. 2014 Long-Term Incentive Equity Plan (the “PAVmed 2014 Equity Plan”) is designed to enable PAVmed to offer employees, officers, directors, and consultants, as defined, an opportunity to acquire shares of common stock of PAVmed. The types of awards that may be granted under the PAVmed 2014 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the PAVmed compensation committee. A total of 1,835,970 77,379 66,720 432,452 Note 11 — Stock-Based Compensation PAVmed Stock Options PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Weighted Average Remaining Contractual Intrinsic Value (2) Outstanding stock options at December 31, 2023 1,192,458 $ 26.18 7.3 $ — Granted (1) 79,500 $ 2.28 Exercised — $ — Forfeited (36,909 ) $ 12.25 Outstanding stock options at June 30, 2024 (3) 1,235,049 $ 25.06 6.8 $ — Vested and exercisable stock options at June 30, 2024 850,180 $ 32.88 5.9 $ — (1) Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of June 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 60,054 On February 22, 2024, the Company granted 59,500 1.85 390,000 0.7 PAVmed Restricted Stock Awards PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Weighted Average Grant Unvested restricted stock awards as of December 31, 2023 70,527 $ 38.77 Granted 390,000 1.85 Vested (4,064 ) 5.79 Forfeited — — Unvested restricted stock awards as of June 30, 2024 456,463 $ 7.45 Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan The Lucid Diagnostics Inc. 2018 Long-Term Incentive Equity Plan (“Lucid Diagnostics 2018 Equity Plan”) is separate and apart from the PAVmed 2014 Equity Plan discussed above. The Lucid Diagnostics 2018 Equity Plan is designed to enable Lucid Diagnostics to offer employees, officers, directors, and consultants, an opportunity to acquire shares of common stock of Lucid Diagnostics. The types of awards that may be granted under the Lucid Diagnostics 2018 Equity Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Lucid Diagnostics compensation committee. A total of 14,324,038 768,595 523,300 50,000 2,680,038 Note 11 — Stock-Based Compensation Lucid Diagnostics Stock Options Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Weighted Average Remaining Contractual Intrinsic Value (2) Outstanding stock options at December 31, 2023 5,504,383 $ 2.00 8.5 $ 765 Granted (1) 3,519,000 $ 1.23 Exercised (3,333 ) $ 1.31 Forfeited (275,424 ) $ 1.63 Outstanding stock options at June 30, 2024 (3) 8,744,626 $ 1.70 8.6 $ 199 Vested and exercisable stock options at June 30, 2024 3,082,590 $ 2.26 7.3 $ 199 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of June 30, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 523,300 On February 22, 2024 , Lucid granted 2,895,000 stock options with a weighted average exercise price of $ 1.25 vest one-third after one year then ratably over the next eight quarters. Lucid Diagnostics Restricted Stock Awards Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Weighted Average Grant Unvested restricted stock awards as of December 31, 2023 2,337,440 $ 8.99 Granted 1,600,000 1.03 Vested (26,912 ) 4.56 Forfeited (13,088 ) 4.56 Unvested restricted stock awards as of June 30, 2024 3,897,440 $ 5.77 In May 2024, a total of 1,600,000 1.5 Consolidated Stock-Based Compensation Expense The consolidated stock-based compensation expense recognized by each of PAVmed and Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Cost of revenue $ 44 $ 31 $ 80 $ 54 Sales and marketing expenses 387 455 790 899 General and administrative expenses 1,214 1,674 2,292 5,262 Research and development expenses 259 347 624 711 Total stock-based compensation expense $ 1,904 $ 2,507 $ 3,786 $ 6,926 Note 11 — Stock-Based Compensation Stock-Based Compensation Expense Recognized by Lucid Diagnostics As noted, the consolidated stock-based compensation expense presented above is inclusive of stock-based compensation expense recognized by Lucid Diagnostics, inclusive of each of: stock options granted under the PAVmed 2014 Equity Plan to the three physician inventors of the intellectual property underlying the Amended CWRU License Agreement; and stock options and restricted stock awards granted to employees of PAVmed and non-employee consultants under the Lucid Diagnostics 2018 Equity Plan. The stock-based compensation expense recognized by Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 33 $ 16 $ 58 $ 28 Lucid Diagnostics 2018 Equity Plan – sales and marketing 326 247 597 470 Lucid Diagnostics 2018 Equity Plan – general and administrative 609 836 937 3,348 Lucid Diagnostics 2018 Equity Plan – research and development 138 66 258 136 PAVmed 2014 Equity Plan - cost of revenue 11 9 22 16 PAVmed 2014 Equity Plan - sales and marketing 39 120 118 253 PAVmed 2014 Equity Plan - general and administrative 1 8 4 164 PAVmed 2014 Equity Plan - research and development 44 97 141 192 Total stock-based compensation expense – recognized by Lucid Diagnostics $ 1,201 $ 1,399 $ 2,135 $ 4,607 Total stock-based compensation expense $ 1,201 $ 1,399 $ 2,135 $ 4,607 The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense Unrecognized Expense Weighted Average Remaining Service Period (Years) PAVmed 2014 Equity Plan Stock Options $ 2,103 1.7 Restricted Stock Awards $ 660 2.4 Lucid Diagnostics 2018 Equity Plan Stock Options $ 4,665 2.1 Restricted Stock Awards $ 2,305 1.8 Note 11 — Stock-Based Compensation Stock-based compensation expense recognized with respect to stock options granted under the PAVmed 2014 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 1.47 5.25 Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Six Months Ended June 30, 2024 2023 Expected term of stock options (in years) 5.8 5.7 Expected stock price volatility 90 % 88 % Risk free interest rate 4.3 % 3.7 % Expected dividend yield — % — % Stock-based compensation expense recognized with respect to stock options granted under the Lucid Diagnostics 2018 Equity Plan was based on a weighted average estimated fair value of such stock options of $ 0.80 0.87 Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Six Months Ended June 30, 2024 2023 Expected term of stock options (in years) 5.7 5.6 Expected stock price volatility 74 % 75 % Risk free interest rate 4.4 % 3.7 % Expected dividend yield — % — % PAVmed Inc. Employee Stock Purchase Plan (“PAVmed ESPP”) A total of 34,332 38,216 62 182 12,590 300,001 139,863 166,667 Lucid Diagnostics Inc. Employee Stock Purchase Plan (“Lucid ESPP”) A total of 511,884 231,987 353 276 1,500,000 395,886 500,000

Preferred Stock

Preferred Stock	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Preferred Stock	Note 12 — Preferred Stock As of June 30, 2024 and December 31, 2023, there were 1,357,976 1,305,213 PAVmed Series B Convertible Preferred Stock Dividends The Series B Convertible Preferred Stock is issued pursuant to the PAVmed Inc. Certificate of Designation of Preferences, Rights, and Limitations of Series B Convertible Preferred Stock (“Series B Convertible Preferred Stock Certificate of Designation”), has a par value of $ 0.001 3.00 The PAVmed Inc. Series B Convertible Preferred Stock dividends are 8.0 3.00 PAVmed Series B Convertible Preferred Stock Dividends Earned The Series B Convertible Preferred Stock dividends earned are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each of the respective corresponding periods presented in the accompanying unaudited condensed consolidated statement of operations, inclusive of $ 81 161 75 149 PAVmed Series B Convertible Preferred Stock Dividends Declared During the six months ended June 30, 2024, the Company’s board of directors declared an aggregate of approximately $ 158 78 80 52,763 26,123 26,640 During the six months ended June 30, 2023, the Company’s board of directors declared an aggregate of approximately $ 146 72 74 48,738 24,128 24,610 Subsequent to June 30, 2024, in August 2024, the Company’s board of directors declared a PAVmed Series B Convertible Preferred Stock dividend, earned as of June 30, 2024, of $ 81 27,173 The PAVmed Series B Convertible Preferred Stock dividends are recognized as a dividend payable liability only upon the dividend being declared payable by the Company’s board of directors. Accordingly, the dividends declared payable subsequent to the date of the accompanying unaudited condensed consolidated balance sheet were not recognized as a dividend payable liability as the Company’s board of directors had not declared the dividends payable as of each such date.

Common Stock and Common Stock P

Common Stock and Common Stock Purchase Warrants	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Common Stock and Common Stock Purchase Warrants	Note 13 — Common Stock and Common Stock Purchase Warrants Common Stock In February 2023, the Company distributed a proxy statement for a special meeting of shareholders that was held on March 31, 2023 (the “Special Meeting”), at which the Company sought approval of an amendment to the Company’s Certificate of Incorporation, to effect, (i) a reverse split of the Company’s outstanding shares of common stock at a specific ratio, ranging from 1-for-5 1-for-15 250,000,000 50,000,000 1-for-15 every 15 shares of the Company’s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares. On March 7, 2024, the Company received a notice from the Nasdaq Listing Qualifications Department stating that, for the preceding 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities (“MVLS”) had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The notification letter stated that the Company would be afforded 180 calendar days (until September 3, 2024) to regain compliance. In order to regain compliance, the Company’s MVLS must close at $35 million or more for a minimum of ten consecutive business days. During the six months ended June 30, 2024 a total of 34,332 Stock-Based Compensation In the six months ended June 30, 2024, 574,424 980 Debt In the six months ended June 30, 2024, the Company sold 333,299 shares through their at-the-market equity facility for net proceeds of approximately $ 693 , after payment of 3 % commissions. Subsequent to June 30, 2024, as of August 8, 2024, the Company sold 288,067 shares through their at-market equity facility for net proceeds of approximately $ 277 after payment of 3 % commissions. PAVmed Distribution of Lucid Diagnostics Common Stock to Shareholders On February 15, 2024, the Company distributed by special dividend to the Company stockholders 3,331,747 38 100 The Company’s distribution of Lucid common stock to PAVmed stockholders, constituted an “Extraordinary Dividend” as defined in the Warrant Agreement. Accordingly, as a result of the distribution, pursuant to Section 4.3 of the Warrant Agreement, the Warrant Price has been decreased by $ 0.52 0.37709668 23.48 Common Stock Purchase Warrants As of June 30, 2024 and December 31, 2023, Series Z Warrants outstanding totaled 11,937,450 795,830 23.48 24.00 0.52 no

Noncontrolling Interest

Noncontrolling Interest	6 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
Noncontrolling Interest	Note 14 — Noncontrolling Interest The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity June 30, 2024 NCI – equity - December 31, 2023 $ 29,813 Net loss attributable to NCI (7,387 ) Impact of subsidiary equity transactions (2,169 ) Lucid Diagnostics proceeds from issuance of preferred stock Series A-1 5,670 Lucid Diagnostics exchange of preferred stock Series A and Series A-1 (24,294 ) Lucid Diagnostics proceeds from issuance of preferred stock Series B and Series B-1 55,919 Lucid Diagnostics deemed dividend on preferred stock (7,496 ) Lucid Diagnostics issuance of common stock for settlement of vendor service agreement 401 Lucid Diagnostics 2018 Equity Plan stock option exercise 4 Lucid Diagnostics Employee Stock Purchase Plan Purchase 353 Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt 2,541 Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan 1,850 Stock-based compensation expense - Veris Health 2021 Equity Plan 98 NCI – equity - June 30, 2024 $ 55,303 The consolidated NCI presented above is with respect to the Company’s consolidated subsidiaries as a component of consolidated total stockholders’ equity as of June 30, 2024 and December 31, 2023; and the recognition of a net loss attributable to the NCI in the unaudited condensed consolidated statement of operations for the periods beginning on the acquisition date of the respective subsidiaries. Lucid Diagnostics As of June 30, 2024, there were 49,344,945 31,302,444 On January 26, 2024 PAVmed elected to receive payment of $ 4,675 3,331,771 3,331,747 On March 7, 2023, Lucid issued 13,625 1,000 1.394 20 13.625 On March 13, 2024, Lucid issued an additional 5,670 5.67 On March 13, 2024, Lucid issued 44,285 1.2444 5,670 5.67 18.1 As a result of 100 Note 14 — Noncontrolling Interest On May 6, 2024, Lucid issued approximately 11,634 0.7228 11.6 Deemed Dividend on Series A and Series A-1 Convertible Preferred Stock Exchange Offer The fair value of the consideration given in the form of the issue of 44,285 12,495 24,294 7.5 Schedule of Net Loss Attributable to Common Stockholders Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer March 13, 2024 Fair Value - 44,285 $ 44,285 Less: Fair value related to newly issued Series B Preferred Stock (of 12,495 (12,495 ) Less: Carrying value related to Series A and Series A-1 Preferred Stock Exchanged for Series B Preferred Stock (of 24,295 (24,294 ) Deemed Dividend Charged to Accumulated Deficit $ 7,496

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Net Loss Per Share	Note 15 — Net Loss Per Share The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator Net loss - before noncontrolling interest $ (14,914 ) $ (17,892 ) $ (33,426 ) $ (40,106 ) Net loss attributable to noncontrolling interest 4,087 3,355 7,387 7,638 Net loss - as reported, attributable to PAVmed Inc. $ (10,827 ) $ (14,537 ) $ (26,039 ) $ (32,468 ) Series B Convertible Preferred Stock dividends – earned $ (81 ) $ (75 ) $ (161 ) $ (149 ) Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests $ — $ — $ (7,496 ) $ — Net loss attributable to PAVmed Inc. common stockholders $ (10,908 ) $ (14,612 ) $ (33,696 ) $ (32,617 ) Denominator Weighted average common shares outstanding, basic and diluted 9,152,819 6,956,655 8,923,862 6,716,169 Net loss per share (1) Basic and diluted Net loss attributable to PAVmed Inc. common stockholders $ (1.19 ) $ (2.10 ) $ (3.78 ) $ (4.86 ) (1) - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated. The common stock equivalents have been excluded from the computation of diluted weighted average shares outstanding as their inclusion would be anti-dilutive, are as follows: The Series B Convertible Preferred Stock dividends earned as of each of the respective years noted, are included in the calculation of basic and diluted net loss attributable to PAVmed common stockholders for each respective period presented. Notwithstanding, the Series B Convertible Preferred Stock dividends are recognized as a dividend payable only upon the dividend being declared payable by the Company’s board of directors. Note 15 — Net Loss Per Share Basic weighted-average number of shares of common stock outstanding for the six month periods ended June 30, 2024 and 2023 include the shares of the Company issued and outstanding during such periods, each on a weighted average basis. The basic weighted average number of shares of common stock outstanding excludes common stock equivalent incremental shares, while diluted weighted average number of shares outstanding includes such incremental shares. However, as the Company was in a loss position for all years presented, basic and diluted weighted average shares outstanding are the same, as the inclusion of the incremental shares would be anti-dilutive. The common stock equivalents excluded from the computation of diluted weighted average shares outstanding are as follows: Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share 2024 2023 June 30, 2024 2023 Stock options and restricted stock awards 1,691,512 1,263,715 Series Z Warrants 795,830 795,830 Series B Convertible Preferred Stock 90,532 83,634 Total 2,577,874 2,143,179 The total stock options and restricted stock awards are inclusive of 60,054 33,391

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of PAVmed and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and applicable rules and regulations of the United States Securities and Exchange Commission (“SEC”), and include the accounts of the Company and its wholly-owned subsidiaries, majority-owned subsidiaries and Lucid Diagnostics. All intercompany transactions and balances have been eliminated in consolidation. The Company has a controlling financial interest in each of: Lucid Diagnostics and Veris Health, with the corresponding noncontrolling interest included as a separate component of consolidated stockholders’ equity (deficit), including the recognition in the unaudited condensed consolidated statement of operations of a net loss attributable to the noncontrolling interest based on the respective minority-interest equity ownership of each subsidiary. See Note 14, Noncontrolling Interest As permitted under SEC rules, certain footnotes or other financial information normally required by U.S. GAAP have been condensed or omitted. The balance sheet as of December 31, 2023 has been derived from audited consolidated financial statements at such date. The accompanying unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements, and in the opinion of management, include all adjustments, consisting only of routine recurring adjustments, necessary for a fair statement of the Company’s unaudited condensed consolidated financial information. The unaudited condensed consolidated results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the consolidated results to be expected for the year ending December 31, 2024 or for any other interim period or for any other future periods. The accompanying unaudited condensed consolidated financial statements and related unaudited condensed consolidated financial information should be read in conjunction with the Company’s audited consolidated financial statements and related notes thereto as of and for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K as filed with the SEC on March 25, 2024. All amounts in the accompanying unaudited condensed consolidated financial statements and the notes thereto are presented in thousands of dollars, if not otherwise noted as being presented in millions of dollars, except for shares and per share amounts.
Use of Estimates	Use of Estimates In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the unaudited condensed consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. Note 3 — Summary of Significant Accounting Policies
Revenue Recognition	Revenue Recognition Revenues are recognized when the satisfaction of the performance obligation occurs, in an amount that reflects the consideration the Company expects to collect in exchange for those services. The Company’s revenue is primarily generated by its laboratory testing services utilizing its EsoGuard Esophageal DNA tests. The services are completed upon release of a patient’s test result to the ordering healthcare provider. Revenue recognized is inclusive of both variable consideration in connection with an individual patient’s third-party insurance coverage policy and fixed consideration in connection with a contracted services arrangement with an unrelated third party legal entity. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, Revenue from Contracts with Customers, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The key aspects considered by the Company include the following: Contracts Performance obligations Transaction price If the consideration derived from the contracts is deemed to be variable, the Company estimates the amount of consideration to which it will be entitled in exchange for the promised goods or services. The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. In other words, the Company recognizes revenue up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. When the Company does not have significant historical experience or that experience has limited predictive value, the constraint over estimates of variable consideration may result in no revenue being recognized upon delivery of patient EsoGuard test results to the ordering healthcare provider. As such, the Company recognizes revenue up to the amount of variable consideration not subject to a significant reversal until additional information is obtained or the uncertainty associated with additional payments or refunds, if any, is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in estimated expected variable consideration, with the change in estimate recognized in the period of such revised estimate. With respect to a contracted service arrangement, the fixed consideration revenue is recognized on an as-billed basis upon delivery of the laboratory test report with realization of such fixed consideration deemed probable based upon actual historical experience. Allocate transaction price Practical Expedients Note 3 — Summary of Significant Accounting Policies
Fair Value Option (“FVO”) Election	Fair Value Option (“FVO”) Election Under a Securities Purchase Agreement dated March 31, 2022, the Company issued a Senior Secured Convertible Note dated April 4, 2022, referred to herein as the “April 2022 Senior Convertible Note”, and a Senior Secured Convertible Note dated September 8, 2022, referred to herein as the “September 2022 Senior Convertible Note”, which are accounted under the “fair value option election” as discussed below. Under a Securities Purchase Agreement dated March 13, 2023, Lucid Diagnostics issued a Senior Secured Convertible Note dated March 21, 2023, referred to herein as the “Lucid March 2023 Senior Convertible Note”, which is accounted under the “fair value option election” as discussed below. Under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 815, Derivative and Hedging Alternatively, FASB ASC Topic 825, Financial Instruments See Note 9, Financial Instruments Fair Value Measurements Debt
Reclassifications	Reclassifications Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.
Recent Accounting Standards Updates Not Yet Adopted	Recent Accounting Standards Updates Not Yet Adopted In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740)—Improvements to Income Tax Disclosures (“ASU 2023-09”), which is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in ASU 2023-09 provide for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for the Company prospectively to all annual periods beginning after December 15, 2024. Early adoption is permitted. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280)—Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which require public companies disclose significant segment expenses and other segment items on an annual and interim basis and to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. The guidance is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company does not expect the standard to have a significant impact on its unaudited condensed consolidated financial statements. In October 2023, the FASB issued ASU No. 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This update modifies the disclosure or presentation requirements of a variety of topics in the Accounting Standards Codification to conform with certain SEC amendments in Release No. 33-10532, Disclosure Update and Simplification. The amendments in this update should be applied prospectively, and the effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or S-K becomes effective. However, if the SEC has not removed the related disclosure from its regulations by June 30, 2027, the amendments will be removed from the Codification and not become effective. Early adoption is prohibited. The Company is currently evaluating the impact this update will have on its unaudited condensed consolidated financial statements and disclosures.

Prepaid Expenses, Deposits, a_2

Prepaid Expenses, Deposits, and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Prepaid Expenses Deposits And Other Current Assets
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following as of: Schedule of Prepaid Expenses and Other Current Assets June 30, 2024 December 31, 2023 Advanced payments to service providers and suppliers $ 738 $ 739 Prepaid insurance 872 848 Deposits 1,896 2,672 Veris Box supplies 296 261 Total prepaid expenses, deposits and other current assets $ 3,802 $ 4,520

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2024
Leases
Schedule of Future Minimum Lease Payments for Operating Leases	The Company’s future lease payments as of June 30, 2024, which are presented as operating lease liabilities, current portion and operating lease liabilities, less current portion on the Company’s unaudited condensed consolidated balance sheets are as follows: Schedule of Future Minimum Lease Payments for Operating Leases 2024 (remainder of year) $ 909 2025 1,724 2026 1,677 2027 1,507 2028 472 Thereafter 848 Total lease payments $ 7,137 Less: imputed interest (1,103 ) Present value of lease liabilities $ 6,034
Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases	Supplemental disclosure of cash flow information related to the Company’s cash and non-cash activities with its leases are as follows: Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases 2024 2023 Six Months Ended June 30, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 942 $ 705 Non-cash investing and financing activities Right-of-use assets obtained in exchange for new operating lease liabilities $ 2,285 $ 2,689 Weighted-average remaining lease term - operating leases (in years) 4.40 4.75 Weighted-average discount rate - operating leases 7.875 % 7.875 %

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Less Accumulated Amortization	Intangible assets, less accumulated amortization, consisted of the following as of: Schedule of Intangible Assets, Less Accumulated Amortization Estimated Useful Life June 30, 2024 December 31, 2023 Defensive asset 60 $ 2,105 $ 2,105 Laboratory licenses and certifications and laboratory information management software 24 3,200 3,200 Other 1 year 70 70 Total Intangible assets 5,375 5,375 Less Accumulated Amortization (4,428 ) (3,951 ) Intangible Assets, net $ 947 $ 1,424
Schedule of Estimated Amortization Expense for Intangible Assets	Schedule of Estimated Amortization Expense for Intangible Assets 2024 (remainder of year) $ 210 2025 421 2026 316 Total $ 947

Financial Instruments Fair Va_2

Financial Instruments Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis	The fair value hierarchy table for the periods indicated is as follows: Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis Fair Value Measurement on a Recurring Basis at Reporting Date Using 1 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total June 30, 2024 Senior Secured Convertible Note - April 2022 $ — $ — $ 19,200 $ 19,200 Senior Secured Convertible Note - September 2022 — — 13,600 13,600 Lucid Senior Secured Convertible Note - March 2023 — — 11,200 11,200 Totals $ — $ — $ 44,000 $ 44,000 Level-1 Inputs Level-2 Inputs Level-3 Inputs Total December 31, 2023 Senior Secured Convertible Note - April 2022 $ — $ — $ 19,000 $ 19,000 Senior Secured Convertible Note - September 2022 — — 11,250 11,250 Lucid Senior Secured Convertible Note - March 2023 — — 13,950 13,950 Totals $ — $ — $ 44,200 $ 44,200 1 There were no transfers between the respective Levels during the six months ended June 30, 2024.
Schedule of Fair Value Assumption Used	The estimated fair value of the April 2022 Senior Convertible Note, the September 2022 Senior Convertible Note and the Lucid March 2023 Senior Convertible Note as of each of June 30, 2024 and December 31, 2023, were computed using a Monte Carlo simulation of the present value of its cash flows using a synthetic credit rating analysis and a required rate-of-return, using the following assumptions: Schedule of Fair Value Assumption Used April 2022 Senior September 2022 Senior Lucid March 2023 Senior Fair Value $ 19,200 $ 13,600 $ 11,200 Face value principal payable $ 17,602 $ 8,082 $ 9,811 Required rate of return 10.000 % 9.700 % 10.00 % Conversion Price $ 75.00 $ 75.00 $ 5.00 Value of common stock $ 0.82 $ 0.82 $ 0.82 Expected term (years) 0.76 1.19 0.72 Volatility 160.00 % 160.00 % 60.00 % Risk free rate 5.07 % 4.90 % 5.09 % Dividend yield — % — % — % April 2022 Senior September 2022 Senior Lucid March 2023 Senior Fair Value $ 19,000 $ 11,250 $ 13,950 Face value principal payable $ 17,602 $ 9,062 $ 11,019 Required rate of return 10.00 10.50 % 10.00 10.20 % 10.00 % Conversion Price $ 75.00 $ 75.00 $ 5.00 Value of common stock $ 4.12 $ 4.12 $ 1.41 Expected term (years) 0.26 1.26 0.69 1.69 1.22 Volatility 85.00 % 85.00 % 60.00 % Risk free rate 4.54 5.25 % 4.31 4.96 % 4.56 % Dividend yield — % — % — %

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Summary of Outstanding Debt	The fair value and face value principal outstanding of the Senior Convertible Notes as of the dates indicated are as follows: Summary of Outstanding Debt Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,200 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 8,082 13,600 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 9,811 11,200 Balance as of June 30, 2024 $ 35,495 $ 44,000 Contractual Stated Interest Rate Conversion Price per Share Face Value Principal Outstanding Fair Value April 2022 Senior Convertible Note April 4, 2025 7.875 % $ 75.00 $ 17,602 $ 19,000 September 2022 Senior Convertible Note September 8, 2025 7.875 % $ 75.00 9,062 11,250 Lucid March 2023 Senior Convertible Note March 21, 2025 7.875 % $ 5.00 11,019 13,950 Balance as of December 31, 2023 $ 37,683 $ 44,200
Schedule of Changes in Fair Value of Debt	The changes in the fair value of debt during the three and six month periods ended June 30, 2024 is as follows: Schedule of Changes in Fair Value of Debt April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - March 31, 2024 $ 18,800 $ 13,600 $ 13,140 $ 45,540 $ — Installment repayments – common stock — (700 ) (1,125 ) (1,825 ) — Non-installment payments – common stock — (65 ) (216 ) (281 ) — Change in fair value 400 765 (599 ) 566 (566 ) Fair Value at June 30, 2024 $ 19,200 $ 13,600 $ 11,200 $ 44,000 - Other Income (Expense) - Change in fair value – three month period ended June 30, 2024 $ (566 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2023 $ 19,000 $ 11,250 $ 13,950 $ 44,200 $ — Installment repayments – common stock — (980 ) (1,208 ) (2,188 ) — Non-installment payments – common stock — (88 ) (652 ) (740 ) — Change in fair value 200 3,418 (890 ) 2,728 (2,728 ) Fair Value at June 30, 2024 $ 19,200 $ 13,600 $ 11,200 $ 44,000 - Other Income (Expense) - Change in fair value – six month period ended June 30, 2024 $ (2,728 ) Note 10 — Debt The changes in the fair value of debt during the three and six month periods ended June 30, 2023 is as follows: April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - March 31, 2023 $ 20,750 $ 11,650 $ 11,900 $ 44,300 $ — Installment repayments – common stock (1,608 ) — — (1,608 ) — Non-installment payments – common stock (42 ) — — (42 ) — Change in fair value 430 200 (290 ) 340 (340 ) Fair Value at June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 - Other Income (Expense) - Change in fair value – three month period ended June 30, 2023 $ (340 ) April 2022 Senior Convertible Note September 2022 Senior Convertible Note Lucid March 2023 Senior Convertible Note Sum of Balance Sheet Fair Value Components Other Income (expense) Fair Value - December 31, 2022 $ 22,000 $ 11,650 $ — $ 33,650 $ — Fair Value - Beginning of Period $ 22,000 $ 11,650 $ — $ 33,650 $ — Face value principal – issue date — — 11,111 11,111 — Fair value adjustment – issue date — — 789 789 (789 ) Installment repayments – common stock (2,943 ) — — (2,943 ) — Non-installment payments – common stock (208 ) — — (208 ) — Change in fair value 681 200 (290 ) 591 (591 ) Fair Value at June 30, 2023 $ 19,530 $ 11,850 $ 11,610 $ 42,990 - Fair Value - Ending of Period $ 19,530 $ 11,850 $ 11,610 $ 42,990 - Other Income (Expense) - Change in fair value – six month period ended June 30, 2023 $ (1,380 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Stock-Based Compensation Expense	The consolidated stock-based compensation expense recognized by each of PAVmed and Lucid Diagnostics for both the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, with respect to stock options and restricted stock awards as discussed above, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Cost of revenue $ 44 $ 31 $ 80 $ 54 Sales and marketing expenses 387 455 790 899 General and administrative expenses 1,214 1,674 2,292 5,262 Research and development expenses 259 347 624 711 Total stock-based compensation expense $ 1,904 $ 2,507 $ 3,786 $ 6,926
Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics	Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Lucid Diagnostics 2018 Equity Plan – cost of revenue $ 33 $ 16 $ 58 $ 28 Lucid Diagnostics 2018 Equity Plan – sales and marketing 326 247 597 470 Lucid Diagnostics 2018 Equity Plan – general and administrative 609 836 937 3,348 Lucid Diagnostics 2018 Equity Plan – research and development 138 66 258 136 PAVmed 2014 Equity Plan - cost of revenue 11 9 22 16 PAVmed 2014 Equity Plan - sales and marketing 39 120 118 253 PAVmed 2014 Equity Plan - general and administrative 1 8 4 164 PAVmed 2014 Equity Plan - research and development 44 97 141 192 Total stock-based compensation expense – recognized by Lucid Diagnostics $ 1,201 $ 1,399 $ 2,135 $ 4,607 Total stock-based compensation expense $ 1,201 $ 1,399 $ 2,135 $ 4,607
Schedule of Unrecognized Compensation Expense	The consolidated unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options and restricted stock awards issued under each of the PAVmed 2014 Equity Plan and the Lucid Diagnostics 2018 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense Unrecognized Expense Weighted Average Remaining Service Period (Years) PAVmed 2014 Equity Plan Stock Options $ 2,103 1.7 Restricted Stock Awards $ 660 2.4 Lucid Diagnostics 2018 Equity Plan Stock Options $ 4,665 2.1 Restricted Stock Awards $ 2,305 1.8
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	PAVmed stock options granted under the PAVmed 2014 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Weighted Average Remaining Contractual Intrinsic Value (2) Outstanding stock options at December 31, 2023 1,192,458 $ 26.18 7.3 $ — Granted (1) 79,500 $ 2.28 Exercised — $ — Forfeited (36,909 ) $ 12.25 Outstanding stock options at June 30, 2024 (3) 1,235,049 $ 25.06 6.8 $ — Vested and exercisable stock options at June 30, 2024 850,180 $ 32.88 5.9 $ — (1) Stock options granted under the PAVmed 2014 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the PAVmed common stock on each of June 30, 2024 and December 31, 2023 and the exercise price of the underlying PAVmed stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 60,054
Schedule of Restricted Stock Award Activity	PAVmed restricted stock awards granted under the PAVmed 2014 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Weighted Average Grant Unvested restricted stock awards as of December 31, 2023 70,527 $ 38.77 Granted 390,000 1.85 Vested (4,064 ) 5.79 Forfeited — — Unvested restricted stock awards as of June 30, 2024 456,463 $ 7.45
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Six Months Ended June 30, 2024 2023 Expected term of stock options (in years) 5.8 5.7 Expected stock price volatility 90 % 88 % Risk free interest rate 4.3 % 3.7 % Expected dividend yield — % — %
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Schedule of Summarizes Information About Stock Options	Lucid Diagnostics stock options granted under the Lucid Diagnostics 2018 Equity Plan and stock options granted outside such plan are summarized as follows: Schedule of Summarizes Information About Stock Options Number of Weighted Average Remaining Contractual Intrinsic Value (2) Outstanding stock options at December 31, 2023 5,504,383 $ 2.00 8.5 $ 765 Granted (1) 3,519,000 $ 1.23 Exercised (3,333 ) $ 1.31 Forfeited (275,424 ) $ 1.63 Outstanding stock options at June 30, 2024 (3) 8,744,626 $ 1.70 8.6 $ 199 Vested and exercisable stock options at June 30, 2024 3,082,590 $ 2.26 7.3 $ 199 (1) Stock options granted under the Lucid Diagnostics 2018 Equity Plan and those granted outside such plan generally vest one-third in one year then ratably over the next eight quarters, and have a ten-year contractual term from date-of-grant. (2) The intrinsic value is computed as the difference between the quoted price of the Lucid Diagnostics common stock on each of June 30, 2024 and December 31, 2023 and the exercise price of the underlying Lucid Diagnostics stock options, to the extent such quoted price is greater than the exercise price. (3) The outstanding stock options presented in the table above are inclusive of 523,300
Schedule of Restricted Stock Award Activity	Lucid Diagnostics restricted stock awards granted under the Lucid Diagnostics 2018 Equity Plan and restricted stock awards granted outside such plan are summarized as follows: Schedule of Restricted Stock Award Activity Number of Restricted Weighted Average Grant Unvested restricted stock awards as of December 31, 2023 2,337,440 $ 8.99 Granted 1,600,000 1.03 Vested (26,912 ) 4.56 Forfeited (13,088 ) 4.56 Unvested restricted stock awards as of June 30, 2024 3,897,440 $ 5.77
Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions	Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions Six Months Ended June 30, 2024 2023 Expected term of stock options (in years) 5.7 5.6 Expected stock price volatility 74 % 75 % Risk free interest rate 4.4 % 3.7 % Expected dividend yield — % — %

Noncontrolling Interest (Tables

Noncontrolling Interest (Tables)	6 Months Ended
	Jun. 30, 2024
Noncontrolling Interest [Abstract]
Schedule of Noncontrolling Interest of Stockholders' Equity	The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows: Schedule of Noncontrolling Interest of Stockholders' Equity June 30, 2024 NCI – equity - December 31, 2023 $ 29,813 Net loss attributable to NCI (7,387 ) Impact of subsidiary equity transactions (2,169 ) Lucid Diagnostics proceeds from issuance of preferred stock Series A-1 5,670 Lucid Diagnostics exchange of preferred stock Series A and Series A-1 (24,294 ) Lucid Diagnostics proceeds from issuance of preferred stock Series B and Series B-1 55,919 Lucid Diagnostics deemed dividend on preferred stock (7,496 ) Lucid Diagnostics issuance of common stock for settlement of vendor service agreement 401 Lucid Diagnostics 2018 Equity Plan stock option exercise 4 Lucid Diagnostics Employee Stock Purchase Plan Purchase 353 Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt 2,541 Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan 1,850 Stock-based compensation expense - Veris Health 2021 Equity Plan 98 NCI – equity - June 30, 2024 $ 55,303
Schedule of Net Loss Attributable to Common Stockholders	Schedule of Net Loss Attributable to Common Stockholders Series B Convertible Preferred Stock Issuance and Series A/A-1 Exchange Offer March 13, 2024 Fair Value - 44,285 $ 44,285 Less: Fair value related to newly issued Series B Preferred Stock (of 12,495 (12,495 ) Less: Carrying value related to Series A and Series A-1 Preferred Stock Exchanged for Series B Preferred Stock (of 24,295 (24,294 ) Deemed Dividend Charged to Accumulated Deficit $ 7,496

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share	The Net loss per share - attributable to PAVmed Inc. - basic and diluted and Net loss per share - attributable to PAVmed Inc. common stockholders - basic and diluted - for the respective periods indicated - is as follows: Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share 2024 2023 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Numerator Net loss - before noncontrolling interest $ (14,914 ) $ (17,892 ) $ (33,426 ) $ (40,106 ) Net loss attributable to noncontrolling interest 4,087 3,355 7,387 7,638 Net loss - as reported, attributable to PAVmed Inc. $ (10,827 ) $ (14,537 ) $ (26,039 ) $ (32,468 ) Series B Convertible Preferred Stock dividends – earned $ (81 ) $ (75 ) $ (161 ) $ (149 ) Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests $ — $ — $ (7,496 ) $ — Net loss attributable to PAVmed Inc. common stockholders $ (10,908 ) $ (14,612 ) $ (33,696 ) $ (32,617 ) Denominator Weighted average common shares outstanding, basic and diluted 9,152,819 6,956,655 8,923,862 6,716,169 Net loss per share (1) Basic and diluted Net loss attributable to PAVmed Inc. common stockholders $ (1.19 ) $ (2.10 ) $ (3.78 ) $ (4.86 ) (1) - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.
Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share	Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share 2024 2023 June 30, 2024 2023 Stock options and restricted stock awards 1,691,512 1,263,715 Series Z Warrants 795,830 795,830 Series B Convertible Preferred Stock 90,532 83,634 Total 2,577,874 2,143,179

Liquidity and Going Concern (De

Liquidity and Going Concern (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenues	$ 1,000		$ 2,000
Net loss attributable to common stockholders	10,908	$ 14,612	33,696	$ 32,617
Net cash flows used in operating activities			24,765	$ 29,073
Working capital	23,200		23,200
Current liabilities	44,000		44,000		$ 44,200
Cash	$ 25,500		$ 25,500

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	$ 979	$ 166	$ 1,989	$ 612
Cost of revenue	$ 1,666	$ 1,685	$ 3,411	$ 3,030

Schedule of Prepaid Expenses an

Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Prepaid Expenses Deposits And Other Current Assets
Advanced payments to service providers and suppliers	$ 738	$ 739
Prepaid insurance	872	848
Deposits	1,896	2,672
Veris Box supplies	296	261
Total prepaid expenses, deposits and other current assets	$ 3,802	$ 4,520

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments for Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Leases
2024 (remainder of year)	$ 909
2025	1,724
2026	1,677
2027	1,507
2028	472
Thereafter	848
Total lease payments	7,137
Less: imputed interest	(1,103)
Present value of lease liabilities	$ 6,034	$ 4,525

Schedule of Supplemental Balanc

Schedule of Supplemental Balance Sheet Information Related to Cash and Non-cash Activities with Leases (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Leases
Operating cash flows from operating leases	$ 942	$ 705
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 2,285	$ 2,689
Weighted-average remaining lease term - operating leases (in years)	4 years 4 months 24 days	4 years 9 months
Weighted-average discount rate - operating leases	7.875%	7.875%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Leases
Lease term description	the Company entered into additional lease agreements that have commenced and are classified as operating leases, including in June 2024, Lucid exercised a renewal option to extend the lease term on its central laboratory in California for an additional three years through December 31, 2027. The aggregate (undiscounted) rent payments are approximately $2.6 million over the extended lease term
Rent payments	$ 2,600
Operating lease, right-of-use assets	5,771	$ 4,267
Operating lease obligations	6,034	4,525
Operating lease, liability, current	1,369	1,565
Operating lease liability noncurrent	$ 4,665	$ 2,960

Schedule of Intangible Assets,

Schedule of Intangible Assets, Less Accumulated Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 5,375	$ 5,375
Less Accumulated Amortization	(4,428)	(3,951)
Intangible Assets, net	947	1,424
Defensive Asset [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 2,105	$ 2,105
Finite lived intangible asset, useful life	60 months	60 months
Laboratory Information Management Software [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 3,200	$ 3,200
Finite lived intangible asset, useful life	24 months	24 months
Other Infinite Lived Intangible Asset [Member]
Impairment Effects on Earnings Per Share [Line Items]
Total Intangible assets	$ 70	$ 70
Finite lived intangible asset, useful life	1 year	1 year

Schedule of Estimated Amortizat

Schedule of Estimated Amortization Expense for Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024 (remainder of year)	$ 210
2025	421
2026	316
Intangible Assets, net	$ 947	$ 1,424

Intangible Assets, net (Details

Intangible Assets, net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 105	$ 505	$ 477	$ 1,010

Schedule of Financial Liabiliti

Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands		Jun. 30, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	$ 44,000	$ 44,200
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	44,000	44,200
April 2022 Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	19,200	19,000
April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
April 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	19,200	19,000
September 2022 Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	13,600	11,250
September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
September 2022 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	13,600	11,250
Lucid March 2023 Senior Convertible Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	11,200	13,950
Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]
Lucid March 2023 Senior Convertible Note [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liability	[1]	$ 11,200	$ 13,950
[1]There were no transfers between the respective Levels during the six months ended June 30, 2024.

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumption Used (Details) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Sep. 20, 2023 USD ($)	Mar. 21, 2023 USD ($)	Mar. 13, 2023 USD ($)	Sep. 08, 2022 USD ($)	Apr. 04, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value	$ 44,000	$ 44,200
Face value principal payable	35,495	37,683
April 2022 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value	19,200	19,000
Face value principal payable	$ 17,602	$ 17,602					$ 27,500
April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	10
April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10
April 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10.50
April 2022 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	75	75
April 2022 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	0.82	4.12
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years	9 months 3 days
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		3 months 3 days
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		1 year 3 months 3 days
April 2022 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	160	85
April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	5.07
April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.54
April 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		5.25
April 2022 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input
September 2022 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value	$ 13,600	$ 11,250
Face value principal payable	$ 8,082	$ 9,062				$ 11,250
September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	9.700
September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10
September 2022 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		10.20
September 2022 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	75	75
September 2022 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	0.82	4.12
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years	1 year 2 months 8 days
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		8 months 8 days
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years		1 year 8 months 8 days
September 2022 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	160	85
September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	4.90
September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.31
September 2022 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input		4.96
September 2022 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input
Lucid March 2023 Senior Convertible Note [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument fair value	$ 11,200	$ 13,950
Face value principal payable	$ 9,811	$ 11,019	$ 11,100	$ 11,100	$ 11,100
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input Required Rate of Return [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	10	10
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Conversion Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	5	5
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	0.82	1.41
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term years	8 months 19 days	1 year 2 months 19 days
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	60	60
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input	5.09	4.56
Lucid March 2023 Senior Convertible Note [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumption measurement input

Financial Instruments Fair Va_3

Financial Instruments Fair Value Measurements (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Sep. 20, 2023	Mar. 21, 2023	Mar. 13, 2023	Sep. 08, 2022	Apr. 04, 2022
Short-Term Debt [Line Items]
Face value principal payable	$ 35,495	$ 37,683
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable	17,602	17,602					$ 27,500
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable	8,082	9,062				$ 11,250
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Face value principal payable	$ 9,811	$ 11,019	$ 11,100	$ 11,100	$ 11,100

Summary of Outstanding Debt (De

Summary of Outstanding Debt (Details) - USD ($) $ / shares in Units, $ in Thousands					6 Months Ended	12 Months Ended
	Sep. 21, 2023	Mar. 13, 2023	Sep. 08, 2022	Apr. 04, 2022	Jun. 30, 2024	Dec. 31, 2023	Sep. 20, 2023	Mar. 21, 2023
Short-Term Debt [Line Items]
Face Value Principal Outstanding					$ 35,495	$ 37,683
Fair Value					$ 44,000	$ 44,200
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date				Apr. 04, 2024	Apr. 04, 2025	Apr. 04, 2025
Stated Interest Rate				7.875%	7.875%	7.875%
Conversion Price				$ 75	$ 75	$ 75
Face Value Principal Outstanding				$ 27,500	$ 17,602	$ 17,602
Fair Value					$ 19,200	$ 19,000
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date			Sep. 06, 2024		Sep. 08, 2025	Sep. 08, 2025
Stated Interest Rate			7.875%		7.875%	7.875%
Conversion Price			$ 75		$ 75	$ 75
Face Value Principal Outstanding			$ 11,250		$ 8,082	$ 9,062
Fair Value					$ 13,600	$ 11,250
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Maturity Date	Mar. 21, 2025	Mar. 21, 2025			Mar. 21, 2025	Mar. 21, 2025
Stated Interest Rate		7.875%			7.875%	7.875%	7.875%
Conversion Price		$ 5			$ 5	$ 5
Face Value Principal Outstanding		$ 11,100			$ 9,811	$ 11,019	$ 11,100	$ 11,100
Fair Value					$ 11,200	$ 13,950

Schedule of Changes in Fair Val

Schedule of Changes in Fair Value of Debt (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	$ 45,540	$ 44,300	$ 44,200	$ 33,650
Installment repayments – common stock	(1,825)	(1,608)	(2,188)	(2,943)
Non-installment payments – common stock	(281)	(42)	(740)	(208)
Change in fair value	566	340	2,728	591
Fair Value - Ending of Period	44,000	42,990	44,000	42,990
Other Income (Expense) - Change in fair value	(566)	(340)	(2,728)	(1,380)
Face value principal – issue date				11,111
Fair value adjustment – issue date				789
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	18,800	20,750	19,000	22,000
Installment repayments – common stock		(1,608)		(2,943)
Non-installment payments – common stock		(42)		(208)
Change in fair value	400	430	200	681
Fair Value - Ending of Period	19,200	19,530	19,200	19,530
Face value principal – issue date
Fair value adjustment – issue date
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	13,600	11,650	11,250	11,650
Installment repayments – common stock	(700)		(980)
Non-installment payments – common stock	(65)		(88)
Change in fair value	765	200	3,418	200
Fair Value - Ending of Period	13,600	11,850	13,600	11,850
Face value principal – issue date
Fair value adjustment – issue date
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period	13,140	11,900	13,950
Installment repayments – common stock	(1,125)		(1,208)
Non-installment payments – common stock	(216)		(652)
Change in fair value	(599)	(290)	(890)	(290)
Fair Value - Ending of Period	11,200	11,610	11,200	11,610
Face value principal – issue date				11,111
Fair value adjustment – issue date				789
Other Income Expense [Member]
Short-Term Debt [Line Items]
Fair Value - Beginning of Period
Installment repayments – common stock
Non-installment payments – common stock
Change in fair value	(566)	(340)	(2,728)	(591)
Fair Value - Ending of Period
Face value principal – issue date
Fair value adjustment – issue date				$ (789)

Debt (Details Narrative)

Debt (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						3 Months Ended		6 Months Ended		12 Months Ended
	Aug. 08, 2024	Sep. 21, 2023	Mar. 13, 2023	Sep. 08, 2022	Apr. 04, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Sep. 20, 2023	Mar. 21, 2023	Apr. 30, 2022	Mar. 31, 2022
Short-Term Debt [Line Items]
Debt instrument, face amount						$ 35,495		$ 35,495		$ 37,683
Stock Issued During Period, Value, Conversion of Convertible Securities						806	$ 2,395	1,113	$ 4,423
Interest expense						11	228	26	411
Debt Instrument, Fair Value Disclosure						44,000		44,000		44,200
Debt extinguishment losses						763	743	1,132	1,268
Cash [Member]
Short-Term Debt [Line Items]
Notes payable						2,000		2,000
April 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount					$ 27,500	$ 17,602		$ 17,602		$ 17,602
Debt instrument stated percentage					7.875%	7.875%		7.875%		7.875%
Conversion price					$ 75	$ 75		$ 75		$ 75
Debt instrument maturity date					Apr. 04, 2024			Apr. 04, 2025		Apr. 04, 2025
Debt instrument maturity date, description					maturity date the investor agreed to extend by one year, to April 4, 2025
Debt Instrument, Fair Value Disclosure						$ 19,200		$ 19,200		$ 19,000
September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount				$ 11,250		$ 8,082		$ 8,082		$ 9,062
Debt instrument stated percentage				7.875%		7.875%		7.875%		7.875%
Conversion price				$ 75		$ 75		$ 75		$ 75
Debt instrument maturity date				Sep. 06, 2024				Sep. 08, 2025		Sep. 08, 2025
Debt instrument maturity date, description				maturity date the investor agreed to extend by one year, to September 8, 2025.
Debt instrument description				The Company is subject to financial covenants requiring: (i) a minimum of $8.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) the Company’s average market capitalization over the prior ten trading days, to not exceed 30% (the “Debt to Market Cap Ratio Test”); and (iii) the Company’s market capitalization to at no time be less than $75 million
Repayments of Convertible Debt						$ 700		$ 980
Interest Expense, Operating and Nonoperating						$ 65		$ 88
Stock Issued During Period, Shares, Conversion of Convertible Securities						461,963		574,424
Gain (Loss) on Extinguishment of Debt						$ 249		$ 452
Debt Instrument, Fair Value Disclosure						13,600		13,600		$ 11,250
September 2022 Senior Convertible Note [Member] | Interest Rate Floor [Member]
Short-Term Debt [Line Items]
Gain (Loss) on Extinguishment of Debt						209		407
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument stated percentage				82.50%									82.50%
Senior convertible note				1,000,000
Conversion price per share													$ 2.70
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member] | June 30, 2024 Through September 03, 2024 [Member]
Short-Term Debt [Line Items]
Conversion price				$ 0.40
Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount			$ 11,100			$ 9,811		$ 9,811		$ 11,019	$ 11,100	$ 11,100
Debt instrument stated percentage			7.875%			7.875%		7.875%		7.875%	7.875%
Conversion price			$ 5			$ 5		$ 5		$ 5
Debt instrument maturity date		Mar. 21, 2025	Mar. 21, 2025					Mar. 21, 2025		Mar. 21, 2025
Debt instrument description								(i) a minimum of $5.0 million of available cash at all times; (ii) the ratio of (a) the outstanding principal amount of the total senior convertible notes outstanding, accrued and unpaid interest thereon and accrued and unpaid late charges to (b) Lucid’s average market capitalization over the prior ten trading days, as of the last day of any fiscal quarter commencing with September 30, 2023, to not exceed 30%; and (iii) Lucid’s market capitalization to at no time be less than $30 million.
Conversion price per share						$ 0.30		$ 0.30
Repayments of Convertible Debt						$ 1,125		$ 1,208
Stock Issued During Period, Shares, Conversion of Convertible Securities						2,117,833		2,661,181
Proceeds from convertible debt			$ 9,925
Debt instrument fee amount			$ 1,186
Interest expense							$ 219		$ 243
Principal repayment		$ 292
Conversion price, percentage								82.50%
Debt Instrument, Periodic Payment, Interest						$ 215		$ 652
Extinguishment of Debt, Gain (Loss), Net of Tax						512		681
Debt Instrument, Fair Value Disclosure						11,200		11,200		$ 13,950
Lucid March 2023 Senior Convertible Note [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Debt Instrument, Periodic Payment, Interest	$ 80
Extinguishment of Debt, Gain (Loss), Net of Tax	$ 375
Common Stock, Capital Shares Reserved for Future Issuance	747,909
Debt Instrument, Fair Value Disclosure	$ 619
Investor [Member] | September 2022 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities						805		1,113
Investor [Member] | Lucid March 2023 Senior Convertible Note [Member]
Short-Term Debt [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities						$ 1,854		$ 2,541
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount														$ 50,000
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Initial Issuance [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount														27,500
Securities Purchase Agreement [Member] | Accredited Institutional Investor [Member] | Additional Issuance [Member]
Short-Term Debt [Line Items]
Debt instrument, face amount														$ 22,500

Schedule of Summarizes Informat

Schedule of Summarizes Information About Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended		12 Months Ended
		Jun. 30, 2024		Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding, ending balance		66,720
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding, beginning balance		1,192,458
Weighted average exercise price, beginning balance		$ 26.18
Remaining contractual term (years)		6 years 9 months 18 days	[1]	7 years 3 months 18 days
Intrinsic value outstanding, beginning balance	[2]
Number of stock options, granted	[3]	79,500
Weighted average exercise price, granted	[3]	$ 2.28
Number of stock option, exercised
Weighted average exercise price, exercised
Number of stock option, forfeited		(36,909)
Weighted average exercise price, forfeited		$ 12.25
Number of stock options outstanding, ending balance		1,235,049	[1]	1,192,458
Weighted average exercise price, ending balance		$ 25.06	[1]	$ 26.18
Intrinsic value outstanding, ending balance	[2]		[1]
Number of stock options vested and exercisable stock options		850,180
Weighted average exercise price, vested and exercisable stock options		$ 32.88
Remaining contractual term (years), vested and exercisable stock options		5 years 10 months 24 days
Intrinsic value exercisable, ending balance	[2]
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding, beginning balance		5,504,383
Weighted average exercise price, beginning balance		$ 2
Remaining contractual term (years)		8 years 7 months 6 days	[4]	8 years 6 months
Intrinsic value outstanding, beginning balance	[5]	$ 765
Number of stock options, granted	[6]	3,519,000
Weighted average exercise price, granted	[6]	$ 1.23
Number of stock option, exercised		(3,333)
Weighted average exercise price, exercised		$ 1.31
Number of stock option, forfeited		(275,424)
Weighted average exercise price, forfeited		$ 1.63
Number of stock options outstanding, ending balance		8,744,626	[4]	5,504,383
Weighted average exercise price, ending balance		$ 1.70	[4]	$ 2
Intrinsic value outstanding, ending balance	[5]	$ 199	[4]	$ 765
Number of stock options vested and exercisable stock options		3,082,590
Weighted average exercise price, vested and exercisable stock options		$ 2.26
Remaining contractual term (years), vested and exercisable stock options		7 years 3 months 18 days
Intrinsic value exercisable, ending balance	[5]	$ 199
[1]The outstanding stock options presented in the table above are inclusive of 60,054 523,300

Schedule of Summarizes Inform_2

Schedule of Summarizes Information About Stock Options (Details) (Parenthetical) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Number of stock options granted. shares	523,300	523,300
Parent Company [Member] | 2014 Equity Plan [Member]
Number of stock options granted. shares	60,054	60,054

Schedule of Restricted Stock Aw

Schedule of Restricted Stock Award Activity (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2024 $ / shares shares
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares	70,527
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares	$ 38.77
Number of Restricted Stock Awards, Granted | shares	390,000
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 1.85
Number of Restricted Stock Awards, Vested | shares	(4,064)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 5.79
Number of Restricted Stock Awards, Forfeited | shares
Weighted Average Grant Date Fair Value, Forfeited | $ / shares
Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance | shares	456,463
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares	$ 7.45
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Restricted Stock Awards, Unvested restricted stock awards, Beginning balance | shares	2,337,440
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Beginning balance | $ / shares	$ 8.99
Number of Restricted Stock Awards, Granted | shares	1,600,000
Weighted Average Grant Date Fair Value, Granted | $ / shares	$ 1.03
Number of Restricted Stock Awards, Vested | shares	(26,912)
Weighted Average Grant Date Fair Value, Vested | $ / shares	$ 4.56
Number of Restricted Stock Awards, Forfeited | shares	(13,088)
Weighted Average Grant Date Fair Value, Forfeited | $ / shares	$ 4.56
Number of Restricted Stock Awards, Unvested restricted stock awards, Ending balance | shares	3,897,440	[1]
Weighted Average Grant Date Fair Value, Unvested restricted stock awards, Ending balance | $ / shares	$ 5.77	[1]
[1]- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

Schedule of Stock-Based Compens

Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total stock-based compensation expense	$ 1,904	$ 2,507	$ 3,786	$ 6,926
Cost of Revenue [Member]
Total stock-based compensation expense	44	31	80	54
Selling and Marketing Expense [Member]
Total stock-based compensation expense	387	455	790	899
General and Administrative Expense [Member]
Total stock-based compensation expense	1,214	1,674	2,292	5,262
Research and Development Expense [Member]
Total stock-based compensation expense	$ 259	$ 347	$ 624	$ 711

Schedule of Stock-Based Compe_2

Schedule of Stock-Based Compensation Expense Recognized by Lucid Diagnostics (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Total stock-based compensation expense	$ 1,904	$ 2,507	$ 3,786	$ 6,926
Lucid Diagnostics Inc [Member]
Total stock-based compensation expense	1,201	1,399	2,135	4,607
Cost of Revenue [Member]
Total stock-based compensation expense	44	31	80	54
Selling and Marketing Expense [Member]
Total stock-based compensation expense	387	455	790	899
General and Administrative Expense [Member]
Total stock-based compensation expense	1,214	1,674	2,292	5,262
Research and Development Expense [Member]
Total stock-based compensation expense	259	347	624	711
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	33	16	58	28
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	326	247	597	470
Lucid Diagnostics Inc 2018 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	609	836	937	3,348
Lucid Diagnostics Inc 2018 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	138	66	258	136
PAVmed Inc 2014 Equity Plan [Member] | Cost of Revenue [Member]
Total stock-based compensation expense	11	9	22	16
PAVmed Inc 2014 Equity Plan [Member] | Selling and Marketing Expense [Member]
Total stock-based compensation expense	39	120	118	253
PAVmed Inc 2014 Equity Plan [Member] | General and Administrative Expense [Member]
Total stock-based compensation expense	1	8	4	164
PAVmed Inc 2014 Equity Plan [Member] | Research and Development Expense [Member]
Total stock-based compensation expense	$ 44	$ 97	$ 141	$ 192

Schedule of Unrecognized Compen

Schedule of Unrecognized Compensation Expense (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Equity Option [Member] | PAVmed Inc 2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 2,103
Weighted Average Remaining Service Period	1 year 8 months 12 days
Equity Option [Member] | Lucid Diagnostics Inc 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 4,665
Weighted Average Remaining Service Period	2 years 1 month 6 days
Restricted Stock [Member] | PAVmed Inc 2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 660
Weighted Average Remaining Service Period	2 years 4 months 24 days
Restricted Stock [Member] | Lucid Diagnostics Inc 2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized Expense	$ 2,305
Weighted Average Remaining Service Period	1 year 9 months 18 days

Schedule of Fair Values of Stoc

Schedule of Fair Values of Stock Options Granted Using Black-scholes Valuation Model Assumptions (Details)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 9 months 18 days	5 years 8 months 12 days
Expected stock price volatility	90%	88%
Risk free interest rate	4.30%	3.70%
Expected dividend yield
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term of stock options (in years)	5 years 8 months 12 days	5 years 7 months 6 days
Expected stock price volatility	74%	75%
Risk free interest rate	4.40%	3.70%
Expected dividend yield

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended		6 Months Ended
		Feb. 22, 2024	May 31, 2024	Jan. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2024		Jun. 30, 2023	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							66,720
Proceeds from common stock							$ 984		$ 1,166
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							300,001
Increase in available for grant							139,863
Number of common stock purchased					34,332	38,216
Proceeds from common stock					$ 62	$ 182
Treasury stock						12,590
Increase in reserve stock				166,667
Employee Stock Purchase Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							1,500,000
Increase in available for grant							395,886
Number of common stock purchased					511,884	231,987
Proceeds from common stock					$ 353	$ 276
Increase in reserve stock				500,000
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							1,835,970
Increase in available for grant				432,452			77,379
Number of stock options outstanding							1,235,049	[1]		1,192,458
Granted	[2]						79,500
Weighted average fair value of stock options							$ 1.47		$ 5.25
2014 Equity Plan [Member] | Parent Company [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		59,500
Weighted average exercise price		$ 1.85
2014 Equity Plan [Member] | Parent Company [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted		390,000
Aggregate fair value		$ 700
2018 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options outstanding							8,744,626	[3]		5,504,383
Granted	[4]						3,519,000
Weighted average fair value of stock options							$ 0.80		$ 0.87
2018 Equity Plan [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock capital shares reserved for future issuance							14,324,038
Increase in available for grant				2,680,038			768,595
Granted		2,895,000					523,300
Weighted average exercise price		$ 1.25
Number of restricted stock awards granted, shares							50,000
2018 Equity Plan [Member] | Restricted Stock [Member] | Lucid Diagnostics Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted			1,600,000
Aggregate fair value			$ 1,500
[1]The outstanding stock options presented in the table above are inclusive of 60,054 523,300

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended		12 Months Ended
	Aug. 31, 2024	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Class of Stock [Line Items]
Preferred stock, par value		$ 0.001				$ 0.001		$ 0.001
Dividends earned		$ 81		$ 75		$ 161	$ 149
Aggregate preferred stock dividends earned
Series B Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares outstanding		1,357,976				1,357,976		1,305,213
Preferred stock, par value		$ 0.001				$ 0.001		$ 0.001
Preferred stock stated value per share		$ 3				$ 3
Dividend rate percentage						8%
Dividends earned		$ 81		$ 75		$ 161	149
Aggregate preferred stock dividends declared						$ 158	$ 146
Series B Convertible Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Aggregate preferred stock dividends earned	$ 81
Additioanal aggregate shares of convertible preferred stock	27,173
Series B Convertible Preferred Stock [Member] | Board Of Directors [Member]
Class of Stock [Line Items]
Aggregate preferred stock dividends earned			$ 80		$ 74			$ 78	$ 72
Additioanal aggregate shares of convertible preferred stock			26,640		24,610	52,763	48,738	26,123	24,128

Common Stock and Common Stock_2

Common Stock and Common Stock Purchase Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	6 Months Ended
	Aug. 08, 2024	Feb. 15, 2024	Jan. 15, 2024	Dec. 07, 2023	Nov. 28, 2023	Feb. 28, 2023	Jun. 30, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split					1-for-15
Common stock, shares authorized							50,000,000	50,000,000
Stock Issused and outstanding description				every 15 shares of the Company’s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares.
Debt instrument fee description							On March 7, 2024, the Company received a notice from the Nasdaq Listing Qualifications Department stating that, for the preceding 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities (“MVLS”) had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The notification letter stated that the Company would be afforded 180 calendar days (until September 3, 2024) to regain compliance. In order to regain compliance, the Company’s MVLS must close at $35 million or more for a minimum of ten consecutive business days.
At-the-market equity facility, shares							333,299
At-the-market equity facility, value							$ 693
Payments for commissions percentage							3%
Warrant price decrease		$ 0.52
Share price		0.37709668
Exercise price		$ 23.48
Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price							$ 23.48	$ 23.48
Class of Warrant or Right, Outstanding							11,937,450	11,937,450
Purchase of warrants							795,830	795,830
Exercise price, post reverse-split							$ 24	$ 24
Number of warrants exercised							0
Lucid Diagnostics Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares		3,331,747	38
Lucid Diagnostics Inc [Member] | Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares			100
Subsequent Event [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
At-the-market equity facility, shares	288,067
At-the-market equity facility, value	$ 277
Payments for commissions percentage	3%
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible common stock shares issued upon conversion							574,424
Debt Instrument, Convertible, If-converted Value in Excess of Principal							$ 980
Employee Stock Purchase Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock issued							34,332
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-5
Common stock, shares authorized						50,000,000
Minimum [Member] | Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price, post reverse-split							$ 0.52	$ 0.52
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-15
Common stock, shares authorized						250,000,000

Schedule of Noncontrolling Inte

Schedule of Noncontrolling Interest of Stockholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Noncontrolling Interest [Abstract]
NCI – equity - December 31, 2023			$ 29,813
Net loss attributable to NCI	$ (4,087)	$ (3,355)	(7,387)	$ (7,638)
Impact of subsidiary equity transactions			(2,169)
Lucid Diagnostics proceeds from issuance of preferred stock Series A-1			5,670
Lucid Diagnostics exchange of preferred stock Series A and Series A-1			(24,294)
Lucid Diagnostics proceeds from issuance of preferred stock Series B and Series B-1			55,919
Lucid Diagnostics deemed dividend on preferred stock			(7,496)
Lucid Diagnostics 2018 Equity Plan stock option exercise			4
Lucid Diagnostics Employee Stock Purchase Plan Purchase			353
Conversion of Lucid Diagnostics common stock for Senior Secured Convertible Debt			2,541
Stock-based compensation expense - Lucid Diagnostics 2018 Equity Plan			1,850
Stock-based compensation expense - Veris Health 2021 Equity Plan			98
NCI – equity - June 30, 2024	$ 55,303		$ 55,303

Schedule of Net Loss Attributab

Schedule of Net Loss Attributable to Common Stockholders (Details) $ in Thousands	Mar. 13, 2024 USD ($)
Noncontrolling Interest [Abstract]
Fair Value - 44,285 shares of Series B Preferred Stock issued	$ 44,285
Less: Fair value related to newly issued Series B Preferred Stock (of 12,495 shares)	(12,495)
Less: Carrying value related to Series A and Series A-1 Preferred Stock Exchanged for Series B Preferred Stock (of 24,295 shares)	(24,294)
Deemed Dividend Charged to Accumulated Deficit	$ 7,496

Schedule of Net Loss Attribut_2

Schedule of Net Loss Attributable to Common Stockholders (Details) (Parenthetical)	Mar. 13, 2024 shares
Noncontrolling Interest [Abstract]
Fair value of series B preferred stock issued shares	44,285
Less fair value related to newly issued series B preferred stock shares	12,495
Less carrying value related to series and series A1 preferred stock exchanged for series B preferred stock shares	24,295

Noncontrolling Interest (Detail

Noncontrolling Interest (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands							6 Months Ended
	May 06, 2024	Mar. 13, 2024	Feb. 15, 2024	Jan. 26, 2024	Jan. 15, 2024	Mar. 07, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Noncontrolling Interest [Line Items]
Common stock shares outstanding							9,554,381		8,578,505
Issuance of shares, stated value							$ 0.001		$ 0.001
Gross proceeds							$ 29,798	$ 13,625
Debt instrument fair value							44,000		$ 44,200
Preferred stock carrying value							$ 24,294
Series A Convertible Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued, additional						13,625
Issuance of shares, stated value						$ 1,000
Preferred shares conversion price						$ 1.394
Dividend percentage						20%
Sale of stock, transaction value						$ 13,625
Series A-1 Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued, additional		5,670
Gross proceeds		$ 5,670
Series B Convertible Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued, additional		44,285
Issuance of shares, stated value							$ 0.001		$ 0.001
Dividend percentage							8%
Gross proceeds, sale of shares		$ 18,100
Shares of convertible preferred stock		44,285
Debt instrument fair value		$ 12,495
Preferred stock carrying value		24,294
Fair value of deemed dividend		$ 7,500
Series A-1 and Series B Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Conversion price		$ 1.2444
Lucid Series A and Lucid Series A-1 Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Outstanding shares, percentage		100%
Series B 1 Preferred Stock [Member]
Noncontrolling Interest [Line Items]
Number of shares issued, additional	11,634
Conversion price	$ 0.7228
Gross proceeds, sale of shares	$ 11,600
Lucid Diagnostics Inc [Member]
Noncontrolling Interest [Line Items]
Common stock shares issued							49,344,945
Common stock shares outstanding							49,344,945
Partners capital account units acquisitions							31,302,444
Received from payment of fees				$ 4,675
Number of shares issued, additional				3,331,771
Common stock, dividends shares			3,331,747		38

Schedule of Comparison of Basic

Schedule of Comparison of Basic and Fully Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Net loss - before noncontrolling interest		$ (14,914)	$ (17,892)	$ (33,426)	$ (40,106)
Net loss attributable to noncontrolling interest		4,087	3,355	7,387	7,638
Net loss - as reported, attributable to PAVmed Inc.		(10,827)	(14,537)	(26,039)	(32,468)
Series B Convertible Preferred Stock dividends – earned		(81)	(75)	(161)	(149)
Deemed dividend on Subsidiary Preferred Stock attributable to the noncontrolling interests				(7,496)
Net loss attributable to PAVmed Inc. common stockholders		$ (10,908)	$ (14,612)	$ (33,696)	$ (32,617)
Weighted average common shares outstanding, basic		9,152,819	6,956,655	8,923,862	6,716,169
Weighted average common shares outstanding, diluted		9,152,819	6,956,655	8,923,862	6,716,169
Net loss attributable to PAVmed Inc. common stockholders, diluted	[1]	$ (1.19)	$ (2.10)	$ (3.78)	$ (4.86)
Net loss attributable to PAVmed Inc. common stockholders, basic	[1]		$ (2.10)		$ (4.86)
[1]- Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Diluted Earnings Per Share (Details) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,577,874	2,143,179
Stock Options and Restricted Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,691,512	1,263,715
Series Z Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	795,830	795,830
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	90,532	83,634

Net Loss Per Share (Details Nar

Net Loss Per Share (Details Narrative) - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
2014 Equity Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options issued	60,054	33,391